LAPATINIB plus LETROZOLE or CAPECITABINE AS FIRST LINE TREATMENT OF ER+/HER2+ METASTIC BREAST CANCER - A phase IIb randomized study with built-in crossover

Trial Profile

LAPATINIB plus LETROZOLE or CAPECITABINE AS FIRST LINE TREATMENT OF ER+/HER2+ METASTIC BREAST CANCER - A phase IIb randomized study with built-in crossover

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2012

At a glance

  • Drugs Lapatinib (Primary) ; Capecitabine; Letrozole
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Tipicall
  • Most Recent Events

    • 29 Dec 2012 Status changed from recruiting to discontinued as reported by EudraCT.
    • 20 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top